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Background: Neuroblastoma is a paediatric cancer which originates from precursor cells of the sympathetic
nervous system and accounts for 15% of childhood cancer mortalities. With regards to the role of miRNAs in
neuroblastoma, miR-34a, mapping to a chromosome 1p36 region that is commonly deleted, has been found to act
as a tumor suppressor through targeting of numerous genes associated with cell proliferation and apoptosis.
Methods: A synthetic miR-34a (or negative control) precursor molecule was transfected into NB1691
luc and SK-N-
AS
luc neuroblastoma cells. Quantitative PCR was used to verify increased miR-34a levels in NB1691
luc and SK-N-AS
luc
cell lines prior to in vitro and in vivo analysis. In vitro analysis of the effects of miR-34a over expression on cell
growth, cell cycle and phosphoprotein activation in signal transduction pathways was performed. Neuroblastoma
cells over expressing miR-34a were injected retroperitoneally into immunocompromised CB17-SCID mice and
tumor burden was assessed over a 21 day period by measuring bioluminescence (photons/sec/cm
2).
Results: Over expression of miR-34a in both NB1691
luc and SK-N-AS
luc neuroblastoma cell lines led to a significant
decrease in cell number relative to premiR-negative control treated cells over a 72 hour period. Flow cytometry
results indicated that miR-34a induced cell cycle arrest and subsequent apoptosis activation. Phosphoprotein
analysis highlighted key elements involved in signal transduction, whose activation was dysregulated as a result of
miR-34a introduction into cells. As a potential mechanism of miR-34a action on phosphoprotein levels, we
demonstrate that miR-34a over-expression results in a significant reduction of MAP3K9 mRNA and protein levels.
Although MAP3K9 is a predicted target of miR-34a, direct targeting could not be validated with luciferase reporter
assays. Despite this fact, any functional effects of reduced MAP3K9 expression as a result of miR-34a would be
expected to be similar regardless of the mechanism involved. Most notably, in vivo studies showed that tumor
growth was significantly repressed after exogenous miR-34a administration in retroperitoneal neuroblastoma
tumors.
Conclusion: We demonstrate for the first time that miR-34a significantly reduces tumor growth in an in vivo
orthotopic murine model of neuroblastoma and identified novel effects that miR-34a has on phospho-activation of
key proteins involved with apoptosis.
Background
MicroRNAs (miRNAs) are noncoding RNA molecules
which act as post-transcriptional regulators of specific
messenger RNA transcripts (mRNAs), resulting in tar-
geted degradation and suppression of gene expression.
MiRNAs play major roles in normal developmental pro-
cesses [1,2], and their dysregulation significantly
contributes to various aspects of carcinogenesis in nearly
all forms of cancer, negatively regulating both tumor
suppressor and oncogenes [3]. As reviewed by Stallings
et al., miRNAs play particularly important roles in the
pathogenesis of neuroblastoma, a paediatric cancer ori-
ginating from precursor cells of the sympathetic nervous
system [4,5]. Neuroblastomas are particularly proble-
matic in that some genetic subtypes, such as those exhi-
biting amplification of the MYCN oncogene or deletion
of chromosome 11q, are associated with very poor
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chemotherapy.
MiR-34a maps to the distal region of chromosome 1p
which is commonly deleted in neuroblastoma and was
first identified as having a tumor suppressive function in
neuroblastoma [6]. Tumors with loss of 1p are more
commonly of the MYCN amplified variety (see Stallings
for review [7]). Specifically, in the study by Welch et al.,
[6] and in later studies [8,9], ectopic over-expression of
miR-34a in neuroblastoma cell lines resulted in the acti-
vation of a caspase-mediated apoptotic pathway. The
importance of miR-34a in cancer is now firmly estab-
lished, having tumor suppressive effects in multiple
types of cancer, including leukemias [10], hepatocellular
carcinoma [11], pancreatic [12] and colon [13], among
others. MiR-34a has multiple experimentally validated
targets involved with cellular proliferation and apoptosis,
such as MYCN, BCL2, SIRT1, SFRP1 CAMTA1,
NOTCH1, JAG1, CCND1, CDK6 and E2F3 [6,9,14-19].
Notably, miR-34a is directly up-regulated by p53
[14,20-22] and a related family member, miR-34c, also
has tumor suppressive affects [8,23,24].
Although the direct effects of miR-34a over-expression
have been studied in a wide range of cancer cells
in vitro, relatively few in vivo studies involving miR-34a
have been reported. Transient transfection of glioblas-
toma cells with synthetic miR-34a subsequently affected
tumor growth in a murine xenograft model [25]. Addi-
tionally, the in vivo tumor suppressive effects of miR-
34a were noted in a human xenograft model of colon
cancer as a result of tumor-site administration of solubi-
lised synthetic miR-34a [13] and in a xenograft model of
lung cancer [26,27]. It was therefore of interest to evalu-
ate the role of miR-34a in vivo in an orthotopic murine
model of neuroblastoma through assessment of tumor
growth and moribundity relative to control miRNA trea-
ted cohorts.
Although, as previously mentioned, a number of miR-
34a direct targets have been identified, the down-stream
effects of miR-34a are still poorly understood. Chang
et al., carried out Affymetrix gene expression profiling
in HCT116 pancreatic cancer cells with, and without,
miR-34a over expression [20]. Interestingly, the presence
of miR-34a resulted in the up-regulation of 532 mRNA
transcripts and the corresponding reduction in 681
mRNA transcripts. Gene transcripts which were down
r e g u l a t e ds h o w e ds i g n i f i c a n te n r i c h m e n to fm i R - 3 4 a
binding sites in the 3’UTR; however, the additional
increase in gene expression indicates the broad range of
genes which are affected, downstream of direct target
binding, which might be involved in miR-34a-induced
apoptosis. Identification of varied transcript expression
of several genes involved in MAPK signalling in pan-
creatic cancer cells [20], lung cancer cells [27] and also
the identification of MAP3K9 as a predicted target of
miR-34a, led to our interest in the relevance of altera-
tions in activated phosphoproteins involved in signal
transduction, in response to miR-34a over expression.
Methods
Cell Lines and Transfection Experiments
Kelly, NB1691
luc and SK-N-AS
luc cell lines were main-
tained in RPMI-1640 supplemented with heat-inactivated
foetal bovine serum (10%), l-glutamine (1%) and 100 μg/
mL Zeocin (InVivoGen, San Diego, California). Although
Kelly and SK-N-AS cell lines have been well character-
ized by aCGH for DNA copy number alterations, neither
the NB1691
luc line, nor the luciferase expressing subline
of SK-N-AS, have ever been characterized by aCGH.
aCGH analysis of all four cell lines used in this study
is detailed in Additional File 1, Figure S1a-d. Kelly and
SK-N-AS lines had all of the genomic imbalances identi-
fied in prior publications, while the SK-N-AS
luc line was
identical in all respects to the parental SK-N-AS line.
NB1691
luc exhibited MYCN and MDM2 amplification, as
previously noted [28].
The Pre-miR™ to miR-34a (30 μM) and the premiR-
negative control miRNA (negative control 1, Applied
Biosystems) were reverse transfected into NB1691
luc and
SK-N-AS
luc cell lines using the transfection agent
siPORT™ NeoFX™ (Applied Biosystems/Ambion, Aus-
tin, TX). Cell culture-transfection media was changed
after 24 hours and replaced with pre-warmed standard
cell culture media. In experiments where qPCR was
intended for analysis, total RNA/miRNA was extracted
48 hours post-transfection using RNeasy Kit/miRNeasy
©
kit (Qiagen Inc, Valencia, CA).
Reverse transcription and Real-time qPCR
Reverse transcription was carried out using 50 ng of
total RNA with a primer specific for miR-34a and the
TaqMan microRNA reverse transcription kit (Applied
Biosystems). Quantitative PCR (qPCR) was carried out
on the 7900 HT Fast Real-time System (Applied Biosys-
tems). RNU66, a small RNA encoded in the intron of
RPL5 (chr1:93,018,360-93,018,429; 1p22.1), was used for
normalization in miRNA studies and b-actin was used
for normalization in gene expression studies. A relative
fold change in expression of the target miRNA/gene




Total protein was isolated from cells using a radioimmu-
noprecipitation assay (RIPA) lysis buffer (Sigma-Aldrich
C o r p . ,S t .L o u i s ,M O ) .P r o t e in concentration was mea-
sured using the BCA assay from Millipore (Millipore
Corp., Billerica, USA). Proteins were fractionated on 10%
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membrane. The membrane was probed with the Anti-
MAP3K9 C-terminal antibody (Abcam, Cambridge, MA
#ab71628) and anti b-Actin (Abcam, Cambridge, MA
#ab8226 ) was used as a loading control. Signal was
detected using Immoblion Western (Millipore Corp.,
Billerica, USA).
Luciferase reporter assays
A 1,140 bp region of the 3’UTR of MAP3K9 containing
the predicted miR-34a binding site was inserted into
the dual luciferase PsiCheck2 reporter vector (Pro-
mega), designated Psi/miR-34a (Additional File 2,
Figure S2a). As a negative control, a 5 nt mutation was
introduced into the miR-34a seed region of this
sequence, designated Psi/miR-34amut (Additional File
2, Figure S2b). Kelly, NB1691 or SK-N-AS cells were
plated in 6 well format, and co-transfected using Lipo-
fectamine 2000 with either 2 μg of Psi/miR-34a or Psi/
miR-34amut, along with either 30 nm of either the
Pre-miR-34a or a scrambled oligonucleotide negative
control. Luciferase activity was measured after 24, 48
and 72 hours using a Viktor Plate Reader (Additional
File 3, Figure S3A-F)
Growth Curve and Cell cycle analysis
In vitro experiments were carried out in triplicate in 6
well plates. Neuroblastoma cells (3 × 10
5) were reverse
transfected with premiR-34a or premiR-negative control
and an additional set of wells remained untreated (non-
transfected). At the appropriate time point, 24, 48 and
72 hours post-transfection, cells were trypsinised and
re-suspended in 1 ml of media and nuclei were counted
in triplicate for each sample using a Beckman Coulter
Cell counter (Beckman Coulter Inc, Brea, CA). In addi-
tional experiments, NB1691
luc cells were isolated 48 and
72 hours post-transfection and analysed by flow cytome-
try for DNA content (cell cycle) and Annexin-V staining
(apoptosis, n = 3). Fold change in cell cycle and apopto-
sis, at each time point, was calculated relative to pre-
miR-negative control-treated samples.
Multi-Pathway Signalling Phosphoprotein analysis
NB1691
luc cells were reverse transfected with premiR-34a
and cell pellets were isolated 48 hours post-transfection
and treated with lysis buffer (Millipore Corp., Billerica,
USA) containing phosphatise and protease inhibitors.
Cell debris was removed by centrifugation at 14 000 g for
15 min. Equal amounts of soluble protein lysates were
analysed for the level of various phosphorylated proteins
using MILLIPLEX MAP 8-plex Multi-Pathway Signalling
Phosphoprotein kit on the Luminex 200 system (Milli-
pore Corp.).
In vivo tumor establishment and imaging
A l la n i m a le x p e r i m e n t sw e re carried out in 4 week old
CB-17/SCID mice (Charles’ River Laboratories, Wil-
mington, MA) and were performed in accordance with
a protocol approved by the Institutional Animal Care
and Use Committee of St Jude Children’s Research Hos-
pital, Memphis, Tennessee. Retroperitoneal tumors were




luc cells behind the left adrenal gland via a left
subcostal incision during administration of isoflurane
(2%). Mice received an intraperitoneal injection of
D-Luciferin (150-mg/kg, Caliper Life Sciences, Hopkinton,
MA) and, five minutes after substrate injection, in vivo
bioluminescence images were obtained using an IVIS
Imaging System 100 Series (Xenogen Corporation, Ala-
meda, CA). All specimens were imaged at a range of 25
cm and acquired images were analyzed using Living
Image Software version 2.5 (Xenogen). In vivo biolumi-
nescence measurements were recorded as photons per
second and the automatic range of interest function of
the Living Image Software was used to analyze tumor
bioluminescence in the retroperitoneal tumors resulting
in a value of photons per second per centimetre
squared (photons/sec/cm
2). Mice were initially imaged
for 1 minute and if an image were saturated, the image
time was reduced by 10-second intervals until saturation
was eliminated.
Statistical analysis
Bioluminescence intensities are reported as the mean
photons/sec/cm
2± SEM. The GraphPad Prism program
(Prism 5, GraphPad Software Inc., La Jolla, CA) was
used to analyze and graphically present all in vitro and
in vivo data. Two-Way ANOVA analysis was used to
analyze significance of cell line growth curves, mi-RNA
expression by qPCR and tumor bioluminescence over
time. A t-test was used to compare cell cycle distribu-
tion, apoptosis induction and phosphoprotein activation.
Mantle-Cox analysis was used to compare overall survi-
val in xenograft cohorts and Wilcoxon Rank Sum Test
was carried out on qPCR expression data for MAP3K9
mRNA transcripts.
Results
Although the phenotypic effects of miR-34a over-expres-
sion have been extensively investigated in a number of
neuroblastoma cell lines, the impact of miR-34a on the
in vivo growth of neuroblastoma tumors using an ortho-
topic mouse model has never been investigated. In
o r d e rt of u r t h e ro u ru n d e r s t a n d i n go ft h ee f f e c t so f
miR-34a as a potential tumor suppressor, we have car-
ried out transfection studies of this miRNA in the con-
text of a well characterized orthotopic mouse model of
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stable, constitutively expressed luciferase reporter con-
struct for measuring tumor growth were used, NB1691
luc
(MYCN amplified) and SK-N-AS
luc (non MYCN
amplified).
The in vitro effects of miR-34a ectopic over-expres-
sion were initially analysed on each of these cell lines.
Mature miRNA-34a mimics (premiR-34a) or a negative
control oligonucleotide (premiR-negative control) were
transiently transfected into SK-N-AS
luc or NB1691
luc
cells resulting in significantly enhanced expression of
miR-34a. MiR-34a over-expression led to a significant
reduction in mRNA levels of five experimentally vali-
dated miR-34a targets, MYCN, BCL2, E2F1, E2F3 and
CDC25A in both cell lines; relative to premiR-negative
control-treated cells (Figure 1A and 1B).
As expected, cell numbers were significantly reduced
from 48 hours post-transfection relative to premiR-
negative control-treated cells in both neuroblastoma cell
lines (Figure 1C and 1D). Flow cytometry analysis of
miR-34a transfected and premiR-negative control-trea-
ted NB1691
luc cells at both 48 and 72 hours post trans-
fection indicated that miR-34a led to a significant
reduction in the number of cells in S phase of the cell
cycle (p < 0.01, biological replicates = 3), an increase in
the percentage of cells in G0/G1 phase (p < 0.001,
Figure 1E) and a substantial increase in cells entering
apoptosis (p < 0.01, Figure 1F), consistent with reports
by Welch et al., and Cole et al. involving SK-N-AS cells
[6,8]. We conclude from these initial experiments that
miR-34a over-expression has a pronounced anti-
proliferative effect on NB1691
luc and SK-N-AS
luc cell lines
cultured in vitro, consistent with prior publications [6,8].
Alterations in cell signalling/phosphoprotein in response
to miR-34 over-expression
Although miR-34a has been shown to directly target key
genes such as MYCN, E2F3 and BCL2, the downstream
effects of miR-34a over-expr e s s i o no ns i g n a lt r a n s d u c -
tion pathways have not been investigated. We have
quantified changes in the phosphorylation status of 8
proteins involved in various different signalling pathways
including PI3K/AKT/mTOR signalling (p70 S6 kinase),
RAS/RAF/MEK signalling (ERK1/2, STAT3, p70 S6
kinase, CREB), JAK/STAT signalling (STAT3, STAT5),
heat shock or death receptor signalling (p38, JNK, IB)
and NF-B signalling (IB) following miR-34a ectopic
over-expression in NB1691
luc cells using the MILLI-
PLEX MAP 8-plex Multi-Pathway Signalling Phospho-
protein Analysis kit, based on Luminex xMAP
technology.
Over expression of miR-34a led to enhanced activation
of ERK/MAP kinase 1/2 (p = 0.002, n = 3; Figure 2). Con-
versely, transfection of cells with synthetic miR-34a led to
a significant reduction in STAT3 (p = 0.04) and p38
phosphorylation (p = 0.009) (Figure 2).
Additionally, c-Jun-N-terminal kinase (JNK) is a key reg-
ulator of apoptosis and, in miR-34a-treated NB1691
luccells,
phosphorylated JNK levels are tending towards a signifi-
cant reduction (p = 0.076) relative to activated JNK levels
in control samples (Figure 2).
miR-34a over-expression results in the down-regulation
of MAP3K9
Based upon the noted alterations in phosphoprotein
activation levels, as discussed above, we examined the
TargetScan miRNA prediction database [30] for poten-
tial kinases that might be direct targets of miR-34a that
could account for these alterations. As illustrated in
Figure 3A, the 3’UTR of MAP3K9 (MLK1) has a 7-mer
complementarity region with the miR-34a seed region,
leading us to examine the effects of miR-34a over




as shown in Figure 3B, the presence of miR-34a led to a
significant reduction in MAP3K9 mRNA and protein
expression in both neuroblastoma cell lines relative to
premiR-negative control treated samples (n = 3). In
order to validate that the 3’ UTR of MAP3K9 is a direct
target of miR-34a, a 1,140 base pair segment of the
MAP3K9 3’ UTR, inclusive of the miR-34a target site,
was cloned into the 3’ region of the luciferase gene in
the PsiCheck2 vector (Psi/miR-34a, Additional File 2,
Figure S2). In addition, a second construct was created
with a 5 base pair mutation within the target seed site
(Psi/miR34amut). As illustrated in Additional File 3,
Figure S3, co-transfection of Psi/miR-34a with mature
miR-34a mimics did not decrease luciferase activity rela-
tive to the negative control. Negative results for these
experiments were obtained at different time points (24,
48 and 72 hrs) and with two cell lines (SK-N-AS and
NB1691), indicating that either the miR-34a affect on
MAP3K9 i sn o tad i r e c te f f e c t ,o rt h a tt h e r ei ss o m e
conformational structural difference between the 3’ UTR
of the reporter versus the native 3’ UTR, which inhibits
miR-34a targeting of the reporter.
MiR-34a has a highly significant tumor suppressor effect
in an orthotopic mouse model of neuroblastoma
Although the role of miR-34a as a potential therapeutic
in vivo has been studied in models of colon cancer [13],
lung cancer [26] and glioblastoma [25] to date the abil-
ity of miR-34a to inhibit neuroblastoma cell growth has
thus far only been investigated in vitro.S i n c es e v e r a l
factors effecting tumor growth cannot be investigated
through cell culture alone, the effects of miR-34a over-
expression in an orthotopic murine model of neuroblas-
toma were investigated.
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Page 4 of 11Figure 1 Growth curves and cell cycle analysis. SK-N-AS
luc and NB1691
luc (1 × 10
6) cells were reverse transfected with premiR-34a (30 μM) or
a premiR-negative control molecule and cell pellets were analysed after 48 hours by qPCR for miR-34a, MYCN, BCL2, E2F1, E2F3 and CDC25A
levels (Figure 1A and B, respectively). Additionally, cells were isolated at 24 hour intervals and nuclei were counted in triplicate for each sample
using a Beckman Coulter Cell counter. Cells treated with synthetic miR-34a showed a marked reduction in cell growth relative to premiR-
negative control-treated groups in both SK-N-AS
luc and NB1691
luc cells (Figure 1C and D, respectively * p = 0.004). In order to extend findings
previously reported by Welch et al., [6] in SK-N-AS cells, premiR-34a- treated NB1691
luc (3 × 10
5) cells were isolated 48 and 72 hours post-
transfection and analysed by flow cytometry. Cell cycle and Annexin-V analysis was carried out on all samples (n = 3) and data was normalised
to premiR-negative control treated cells (Figure 1E and 1). Findings indicate that over expression of miR-34a leads to significant reduction in S
phase progression (*p < 0.01), an increase in G0/G1 initiation (**p < 0.001) and a corresponding increase in apoptosis (*p < 0.01).
Tivnan et al. BMC Cancer 2011, 11:33
http://www.biomedcentral.com/1471-2407/11/33
Page 5 of 11Figure 2 Effects of miR-34a on cellular phosphoprotein activation in NB1691
luc cells. NB1691
luc (1 × 10
6) cells were reverse transfected
with premiR-34a (30 μM) or a premiR-negative control molecule. Protein lysates were isolated after 48 hours and 10 μg of total cell protein was
analysed for phosphoprotein alterations using the MILLIPLEX MAP 8-Plex Multi-Pathway Signalling Phosphoprotein Kit (Millipore Corp.,). ERK/MAP
Kinase 1/2 activation significantly increased in miR-34a treated cells relative to premiR-negative control treated NB1691
luc cells (p < 0.01 n = 3).
Notably, activated STAT3, JNK and p38 levels tended towards a significant reduction relative to premiR-negative control- treated samples (p =
0.046, 0.07 and 0.009 respectively).
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Page 6 of 11Figure 3 Role of MAP3K9 in miR-34a-mediated apoptosis. The 3’UTR of MAP3K9 was identified as a putative target of miR-34a with a 7-mer
complementarity region (Figure 3A). Quantitative PCR and Western Blotting of miR-34a- treated NB1691
luc and SK-N-AS
luc cells was carried out
and both MAP3K9 mRNA transcript and protein levels were shown to significantly decrease relative to premiR-negative control-treated samples
in both cells lines analysed (n = 3). Figure 3C outlines the possible mechanism through which miR-34a might mediate cellular apoptosis,
targeting and suppressing MAP3K9 expression, leading to downstream reduction in JNK, p38, CREB and STAT3 activated protein levels (verified
by phosphoprotein analysis Figure 2).
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negative control were injected retroperitoneally into
CB17-SCID mice (n = 4-6 per group) and tumor growth
was detected through bioluminescence imaging facili-
tated by stable expression of the firefly luciferase gene
in SK-N-AS
luc and NB1691
luc cells. Bioluminescent data
indicates that expression of miR-34a in these murine
models resulted in significant reduction in tumor volume
up to 21 days post injection relative to premiR-negative
control-treated groups (p < 0.001, Figure 4A-D). Control
treated cells (premiR-negative control transfections) did
not yield any significant variations in tumor volume rela-
tive to non-transfected cell induced tumors. Therefore,
the effects which were noted can be considered to be a
direct result of the introduction of miR-34a into the neu-
roblastoma cell, which were then subsequently used for
tumor induction.
Bioluminescence data from tumor growth was col-
lected up to 21 days post-tumor induction in each ani-
mal cohort. Subsequent to this time point, animals were
sacrificed at moribundity. Notably, animals with miR-
34a-treated tumors, both SK-N-AS
luc and NB1691
luc
survived significantly longer than cohorts with premiR-
negative control-treated tumors (Figure 4E and 4F,
respectively; p < 0.003 in both tumor models).
Discussion
This study has demonstrated that ectopic over-expres-
sion of miR-34a in the NB1691 cell line leads to altera-
tions in phosphorylation levels of several key proteins
involved with cell survival or apoptosis, including ERK,
STAT3, P38 and JNK. These phosphorylation changes
can be attributed to the down-regulation of MAP3K9 in
response to miR-34a over-expression. The MAPKinase
signal transduction pathway has been extensively studied
with regards to its biochemical interactions and possibi-
lities of therapeutic target identification (see Pearson for
review [31]). MAP3K9 has been shown to phosphorylate
both MKK7 and MKK4, amongst other target protein
kinases (Figure 3C). Each of these kinases are, in turn,
capable of phosphorylating and activating JNK and p38;
respectively. Similarly, JNK can lead to activation of
CREB and STAT3 transcription factors. With this path-
way in mind, it is of interest to note that MAP3K9 sup-
pression led to a significant reduction in JNK, p38 and
STAT3 activated protein; each of which was verified by
Multi-Pathway Signalling Phosphoprotein analysis. The
identification of a possible pathway through which miR-
34a over expression induces cell death provides a novel
insight into the overall mechanism through which miR-
34a-mediated apoptosis might occur in neuroblastoma.
ERK activation has been investigated with respect to its
role as both a pro-survival and pro-apoptotic molecule;
dependent upon cell type and duration of activation
[32-34]. Notably, miR-34a induced cellular apoptosis of
NB1691
luc neuroblastoma cells leads to a significant
increase in phosphorylation of ERK1/2. Constitutive acti-
vation of STAT3 has been correlated to poor prognosis
in both colorectal cancer [35] and non-small cell lung
cancer [36]. STAT3 inactivation in neuroblastoma cell
lines has been observed in response to various treatments
such as Sorafenib [37] and Curcurbitacin [38]. In this
context, miR-34a over-expression in neuroblastoma cells
and the subsequent inactivation of the STAT3 pathway
appears to be one of the potential mechanisms through
which miR-34a may exert its apoptotic effect in these
cells.
P38 mitogen-activated protein kinases are responsive to
stress stimuli and involved in cell differentiation and apop-
tosis. Studies of pathway activation in lung cancer led to
the identification of activated p38 in all tumor samples
analysed (n = 19); suggesting a role for activated p38 in
tumor progression and maintenance [39]. Concomitant
with this theory is the noted reduction in p38 activation in
NB1691
luc cells in response to miR-34a over-expression, a
treatment which induces cellular apoptosis in neuroblas-
toma cells. Activated JNK has been proven to be both pro-
and anti-apoptotic in a variety of cell lines [40]. Notably,
inhibition of activated JNK led to apoptosis in lung carci-
noma cells supporting findings in NB1691
luc cells where
miR-34a-induced apoptosis reduces JNK activation
[41,42]. In the context of the neuroblastoma cell line SK-
N-SH, it is of interest that inhibition of JNK basal levels
through either a JNK specific inhibitor or through siRNA
mediated knock-down results in increased P53 protein
[43]. Thus, given that P53 directly activates miR-34a tran-
scription [14,20-22], it is possible that miR-34a enhances
its own activation indirectly leading to dephosphorylation
and inactivation of JNK.
Although luciferase reporter assays failed to demon-
strate direct targeting of MAP3K9 by miR-34a, in our
opinion, these negative results do not rule out the possi-
bility of direct targeting, as conformational differences
between the luciferase 3’ UTR and that of the endogen-
ous MAP3K9 could have affected targeting. From a
functional standpoint, down-regulation of MAP3K9 by
miR-34a either through direct targeting or an alternative
secondary mechanism would be expected to have the
same phenotypic consequences.
Identification of miR34a as a potent tumor suppressor
molecule of neuroblastoma in vivo is a highly significant
finding with respect to the development of potential thera-
peutics for this disease. Current therapies for high risk neu-
roblastoma include chemo- and radiation-therapy in an
attempt to hinder tumor relapse. Identification of miRNA-
mediated gene therapies for neuroblastoma provides a
potential alternative with respect to treatment which may
circumvent current issues including chemotherapeutic
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Page 8 of 11Figure 4 Analysis of NB1691
luc and SK-N-AS
luc xenografts. MiR-34a or premiR-negative control-treated SK-N-AS
luc and NB1691
luc cells (4.4 ×
10
5), which were stably transfected with luciferase, were introduced into the retroperitoneal space of CB17-SCID immunocompromised mice (n
= 4-7). Animals were administered an intraperitoneal injection of D-Luciferin (150 mg/kg) and, five minutes after substrate injection, the animals
were imaged using an IVIS Imaging System 100 Series (Xenogen Corporation, Alameda, CA). Imaging was carried out at days 6, 10, 14 and 21
post-tumor cell inoculation and the data analysed and presented as the mean value for each cohort (photons/sec/cm
2) ± SEM (*p < 0.001 and
**p < 0.0001). The bioluminescent images above are representative of the photons/sec/cm
2 values obtained in premiR-negative control-treated
SK-N-AS
luc (Figure 4A and C) and NB1691
luc (Figure 4B and D) animals compared to miR-34a-treated groups. Pre-treatment of both SK-N-AS
luc
and NB1691
luc cells with synthetic miR-34a lead to significant reduction in tumor volume relative to premiR-negative control-treated cell tumors.
Animals were sacrificed at moribundity and Mantle-Cox analysis was used to compare overall survival in xenograft cohorts (Figure 4E represents
SK-N-AS
luc and Figure 4F represents the data obtained for NB1691
luc animals, p < 0.003 for both murine models).
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treatment side effects. Targeted therapeutics utilising
the efficacy of miR34a in this disease state is a novel
area of research in terms of neuroblastoma tumor
treatment.
Conclusions
The role of miRNAs in mediating critical cellular pro-
cesses is an emerging field in cancer genetics. Dysregu-
lation, enhanced expression and selective inhibition of
miRNAs has improved scientific understanding of the
functional role which these regulatory molecules play in
cancer progression and patient prognosis. MiR-34a was
the first miRNA identified as a putative tumor suppres-
sor in neuroblastoma through its direct targeting of
transcription factors and other genes essential for cellu-
lar proliferation. Here we identify, for the first time, the
efficacy of miR-34a in retarding neuroblastoma tumor
growth in vivo in both MYCN amplified (NB1691
luc)
and non-MYCN amplified (SK-N-AS
luc) neuroblastoma
xenografts; and also propose a potential mechanism
through which this might occur. The success which
transient pre-treatment of these cells with miR-34a has
on tumor growth provides rationale for further investi-
gation of the effects of miR-34a in pre-established
tumors in vivo; a task which is currently being underta-
ken by our research team.
Additional material
Additional File 1: Figure S1. Whole genome DNA copy number
plots of neuroblastoma cell lines. Array-CGH profiles for MYCN
amplified cell lines (A) Kelly and (B) NB1619
luc as well as 11q- cell lines
(C) SK-N-AS
luc and (D) SK-N-AS. The y-axis represents the log2 fluorescent
ratios of cell line (Cy3) versus a reference control (Cy5). Chromosomes
are plotted across the x-axis from chromosome 1 to chromosome Y.
Additional File 2: Figure S2. Segment of MAP3K9 3’ UTR cloned into
the PsiCheck2 luciferase reporter plasmid. (A) Wild type sequence
with miR-34a seed region highlighted in yellow. (B) Mutated sequence
with mutated sites within the miR-34a seed region highlighted in green.
Additional File 3: Figure S3. Luciferase reporter assays. SK-N-AS (A, C
and E) and NB1691 (B, D and F) cells were transiently transfected with
Psi/miR34a or Psi/miR34amut plasmid in conjunction with premiR34a or
premiR-negative control molecules. Direct targeting, through luciferase
activity analysis relative to co-expressed renilla activity, could not be
validated in either cell lines at the three time points assessed.
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dependent kinase 6).
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